Santhera licenses novel dyskinesia therapy to Biovail.
D000818:Animals; D018726:Anti-Dyskinesia Agents / Q000191:economics* / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence; D015507:Drugs, Investigational / Q000191:economics / Q000627:therapeutic use; D020820:Dyskinesias / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D007093:Imidazoles / Q000191:economics / Q000627:therapeutic use; D007189:Indans / Q000191:economics / Q000627:therapeutic use
D018726:Anti-Dyskinesia Agents; D015507:Drugs, Investigational; D007093:Imidazoles; D007189:Indans; C480818:fipamezole